Shui-Qing Bi1, Ya Peng2, Zong-Dang Wei1, Sheng-Zhong Yao1, Bin Luo2,3, Ying-Ying Ge2,3, Xiao-Xun Xie2,3, Wei-Xia Nong2,3, Chang Liu1, Shao-Wen Xiao4, Qing-Mei Zhang5,6. 1. Department of Neurosurgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China. 2. Department of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University, Nanning, 530021, China. 3. Central Laboratory, School of Pre-Clinical Medicine, Guangxi Medical University, Nanning, 530021, China. 4. Department of Neurosurgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China. 1402988430@qq.com. 5. Department of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University, Nanning, 530021, China. 940478522@qq.com. 6. Central Laboratory, School of Pre-Clinical Medicine, Guangxi Medical University, Nanning, 530021, China. 940478522@qq.com.
Abstract
OBJECTIVE: Cancer/testis antigen FMR1NB is aberrantly expressed in various types of cancer, but not in normal tissues except for testis. This study aimed to investigate the expression and functional role of FMR1NB in glioma. METHODS: The expression of FMR1NB mRNA and protein was determined using RT-PCR and immunohistochemistry, respectively, in glioma specimens from 83 patients at follow-up. The effects of siRNA-mediated FMR1NB silencing on malignant biological behaviors were evaluated in glioma cell lines A172 and U251. RESULTS: FMR1NB mRNA and protein expression was detected in 58.8% (77/131) and 46.34% (57/123) of glioma tissues, respectively. FMR1NB protein was positively correlated with World Health Organization grade and found to be an independent prognostic marker for poor outcome. Knockdown of FMR1NB induced apoptosis and suppressed proliferation, adhesion, migration, and invasion by modulating the expression of cyclin A, CDK2, caspase-3, E-cadherin, and N-cadherin in A172 and U251 cells. CONCLUSION: Our findings suggest that FMR1NB contributes to the tumorigenesis of glioma cells and may represent a potential prognostic biomarker and an attractive therapeutic target in glioma.
OBJECTIVE: Cancer/testis antigen FMR1NB is aberrantly expressed in various types of cancer, but not in normal tissues except for testis. This study aimed to investigate the expression and functional role of FMR1NB in glioma. METHODS: The expression of FMR1NB mRNA and protein was determined using RT-PCR and immunohistochemistry, respectively, in glioma specimens from 83 patients at follow-up. The effects of siRNA-mediated FMR1NB silencing on malignant biological behaviors were evaluated in glioma cell lines A172 and U251. RESULTS: FMR1NB mRNA and protein expression was detected in 58.8% (77/131) and 46.34% (57/123) of glioma tissues, respectively. FMR1NB protein was positively correlated with World Health Organization grade and found to be an independent prognostic marker for poor outcome. Knockdown of FMR1NB induced apoptosis and suppressed proliferation, adhesion, migration, and invasion by modulating the expression of cyclin A, CDK2, caspase-3, E-cadherin, and N-cadherin in A172 and U251 cells. CONCLUSION: Our findings suggest that FMR1NB contributes to the tumorigenesis of glioma cells and may represent a potential prognostic biomarker and an attractive therapeutic target in glioma.
Authors: Jun Yao; Otavia L Caballero; W K Alfred Yung; John N Weinstein; Gregory J Riggins; Robert L Strausberg; Qi Zhao Journal: Cancer Immunol Res Date: 2013-11-25 Impact factor: 11.151
Authors: Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2017-11-06 Impact factor: 12.300
Authors: Marcelo Freitas; Suzana Malheiros; João Norberto Stávale; Thais Priscila Biassi; Fernando Tadeu Zamunér; Maria de Souza Begnami; Fernando Augusto Soares; Andre Luíz Vettore Journal: Oncotarget Date: 2013-04